Cell Metabolism· Zhiguang Zhou, Zhifeng Cheng, Ping Jin, Guoping Yang, Haifang Wang, Bimin Shi, Qijuan Dong, Xiaoxia Shi, Xiaoguang Shi, Hongyan Shu, Wenli Sun, Chongbing Huang, Shuping Zhao, Li Mao, Wei Wang, Ping Xiong, Xiaowen Chen, Junhang Tian, Haiyan Zhang, Tao Su, Liang Huang, Sofie Bay Simony, Thomas Holst-Hansen, Huiru Yan·· 10 天前AI 评分46
新型GLP-1、GIP和胰高血糖素受体三重激动剂UBT251用于超重或肥胖成人：一项多中心、随机II期临床试验
UBT251, a novel triple GLP-1, GIP, and glucagon receptor agonist, in adults with overweight or obesity: A multicenter, randomized phase 2 trial
AI 导读
UBT251在超重或肥胖成人的多中心、随机II期临床试验中带来显著体重减轻及心血管代谢改善。该药是一种新型GLP-1/GIP/GCG受体三重激动剂，安全性可接受，结果支持开展III期评估。
来源：Cell Metabolism · cell.com